UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JULY 2023

FOR

AGILE BIOREG LTD

CONTENTS OF THE FINANCIAL STATEMENTS for the year ended 31 July 2023

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

AGILE BIOREG LTD

COMPANY INFORMATION for the year ended 31 July 2023

REGISTERED OFFICE:

Suite 7
155 Minories
London
EC3N 1AD

REGISTERED NUMBER:

11501098 (England and Wales)

ACCOUNTANTS:

Plus Accounting
Chartered Accountants
Preston Park House
South Road

Brighton East Sussex BN1 6SB

BALANCE SHEET 31 July 2023

	Notes	31.7.23 £	31.7.22 £
FIXED ASSETS			
Investments	4	24,377	24,377
CURRENT ASSETS			
Debtors	5	93,101	101,275
Cash at bank		1,669	3,378
		94,770	104,653
CREDITORS		· · · · · · · · · · · · · · · · · · ·	,
Amounts falling due within one year	6	(8,818)	(16,360)
NET CURRENT ASSETS		85,952	88,293
TOTAL ASSETS LESS CURRENT			
LIABILITIES		<u>110,329</u>	<u>112,670</u>
CAPITAL AND RESERVES			
Called up share capital	7	100	100
Retained earnings	•	110,229	112,570
SHAREHOLDERS' FUNDS		110,329	112,670
the same and the same are same at the same			<u> </u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 21 April 2024 and were signed by:

A Litsiou - Director

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 July 2023

1. STATUTORY INFORMATION

Agile Bioreg Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover represents the fair value of consideration received or receivable net of VAT and trade discounts.

Revenue from management consultancy is recognised at the point of sale.

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Impairment policy

At each balance sheet date, the company reviews the carrying amount of its assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of an asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Going concern

The director has a reasonable expectation that the company has adequate resources to continue in existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2022 - 1).

Page 3 continued...

NOTES TO THE FINANCIAL STATEMENTS - continued for the year ended 31 July 2023

4. FIXED ASSET INVESTMENTS

	111111111111111111111111111111111111111				Other investments £
	COST				~
	At 1 August 20	022			
	and 31 July 20	23			24,377
	NET BOOK V				
	At 31 July 202				<u>24,377</u>
	At 31 July 202	2			<u>24,377</u>
5.	DEBTORS: A	MOUNTS FALLING DUE WITHIN O	NE YEAR		
				31.7.23	31.7.22
				£	£
	Amounts owed	by associates		90,342	89,814
	Other debtors			2,759	<u> 11,461</u>
				<u>93,101</u>	101,275
6.	CREDITORS	: AMOUNTS FALLING DUE WITHIN	NONE YEAR		
				31.7.23	31.7.22
				£	£
	Trade creditors			170	<u>-</u>
	Taxation and s			-	10,785
	Other creditors			8,648	5,575
				<u>8,818</u>	<u>16,360</u>
7.	CALLED UP	SHARE CAPITAL			
	Allotted, issue	d and fully paid:			
	Number:	Class:	Nominal	31.7.23	31.7.22
			value:	£	£
	100	Ordinary	£1	<u> 100</u>	<u> 100</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.